CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows (used in) from Operating Activities:
Net loss	$ (331,330)	$ (14,649)
Adjustments to reconcile net loss to net cash (used in) from operating activities:
Depreciation and amortization expense	54,473	38,872
Change in fair value of contingent consideration	(15,900)	(10,425)
Change in fair value of warrant liabilities	(331)	(57,337)
Loss on extinguishment of debt	0	1,428
Fixed asset abandonment	1,709	0
Amortization of debt issuance costs	2,560	1,570
Non-cash lease expense	1,642	3,642
Stock-based compensation, net	11,368	31,600
Paid in kind interest expense	7,380	0
Credit loss on other assets	62,000	0
Changes in operating assets and liabilities:
Accounts receivable, net	126,652	(67,557)
Other assets	(649)	7,158
Prepaid expenses and other current assets	654	(17,834)
Interest accrued due to sellers	0	100
Accounts payable and accrued expenses (Related parties comprised $(295) and $1,331 for the six months ended June 30, 2023 and 2022, respectively)	28,289	(9,362)
Other liabilities	6,528	10,621
Net cash (used in) provided by operating activities	(44,955)	(82,173)
Cash Flows (used in) from Investing Activities:
Purchase of property and equipment (Related parties comprised $766 and $3,567 for the six months ended June 30, 2023 and 2022, respectively)	(11,270)	(20,431)
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired	0	(4,995)
Payments to sellers	(6,431)	(3,847)
Net cash (used in) provided by investing activities	(17,701)	(29,273)
Cash Flows (used in) from Financing Activities:
Payments of long-term debt	(3,223)	(3,222)
Debt issuance costs	(9,256)	(88)
Proceeds from long-term debt	150,000	0
Proceeds from CS Revolving Line of Credit	55,000	0
Repayments of CS Revolving Line of Credit	(129,000)	0
Proceeds from insurance financing arrangements	2,690	2,529
Payments of principal on insurance financing arrangements	(1,467)	(1,380)
Other	(1,696)	(1,716)
Net cash (used in) provided by financing activities	63,048	(3,877)
Net increase (decrease) in cash, cash equivalents and restricted cash	392	(115,323)
Cash, cash equivalents and restricted cash at beginning of year	27,329	163,170
Cash, cash equivalents and restricted cash at end of period	27,721	47,847
Supplemental cash flow information:
Interest paid	40,476	27,670
Income taxes paid	0	82
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange of lease liabilities	16,558	50,297
Issuance of Class A common stock for acquisitions	14,402	15,771
Due to sellers in connection with acquisitions	0	3,533
Addition to construction in process funded through accounts payable	906	3,580
Humana Affiliate Provider clinic leasehold improvements	363	2,928
Employee Stock Purchase Plan issuance	1,143	9,707
Warrants issued	$ 45,698	$ 0